Clin2
NCT06044623Possibly a fitRecruiting

Tailoring cancer pill dosing for older adults with breast cancer

Metastatic Breast CancerAdvanced Breast CancerQuality of LifeToxicityOlder Patients

Treatments studied

Part of Cancer, Skin clinical trials.

This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
495 people
Ages
70 years and older
Study type
Interventional

Who can take part

  • You are 70 years old or older.
  • You have advanced breast cancer that is hormone receptor-positive (HR+) and HER2-negative, and it cannot be cured with standard treatments.
  • You have not received any systemic therapy (like chemotherapy or hormone therapy) for advanced breast cancer, though you may have taken hormone therapy for up to 28 days before starting this trial.
  • If you have had breast cancer treatment before (like surgery or hormone therapy) and it came back more than 12 months after finishing a CDK 4/6 inhibitor, you may still qualify.
  • You are able to swallow capsules and have adequate organ function.
  • You do not have rapidly progressing disease (visceral crisis) or a history of other cancers in the past 3 years (except certain minor skin cancers).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06377852Recruiting· Phase 3
CDK4/6 inhibitor dosing study for older adults with metastatic breast cancer

This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.

Chandler, Arizona
NCT06275958Recruiting· Phase 3
Lower starting chemo dose for older adults with metastatic colorectal cancer

This study tests whether starting with a lower dose of chemotherapy works as well as the standard dose for people aged 70 and older with metastatic colorectal cancer. The goal is to find a treatment that is effective but gentler, with fewer side effects.

's-Hertogenbosch
NCT07273357Recruiting
CDK4/6 inhibitors for older breast cancer patients

This study looks at how well older breast cancer patients (70 years and older) do when treated with a type of drug called a CDK4/6 inhibitor along with hormone therapy after surgery. The goal is to use simple health checks to help doctors decide if this treatment is right for you.

Gävle
NCT07826052Not yet recruiting· Phase 2
Skipping chemotherapy for older women with hormone-positive breast cancer

This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.

NCT07005557Not yet recruiting· Phase 3
Hormone therapy alone for older women with early breast cancer

This trial tests whether a pill (a CDK4/6 inhibitor) used alone, without chemotherapy, is effective for older women with early-stage hormone-positive breast cancer. The goal is to reduce the risk of cancer returning while avoiding the side effects of chemo.

NCT07399808Recruiting
CDK4/6 Inhibitors in Older Breast Cancer Patients

This study looks at how well CDK4/6 inhibitors work in older adults with breast cancer who are taking these drugs after surgery to help prevent the cancer from coming back. It will follow patients over time to learn more about their experiences.

Pavia, Pavia

Hear when a new Metastatic Breast Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.